Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.23.5 (
cathepsin D
)
4,130
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The X-linked disorder
Lowe syndrome
arises from mutations in
OCRL1
, a lipid phosphatase that hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP(2)). Most patients with
Lowe syndrome
develop proteinuria very early in life. PIP(2) dynamics are known to modulate numerous steps in membrane trafficking, and it has been proposed that
OCRL1
activity regulates the biogenesis or trafficking of the multiligand receptor megalin. To examine this possibility, we investigated the effects of siRNA-mediated
OCRL1
knockdown on biosynthetic and postendocytic membrane traffic in canine and human renal epithelial cells. Cells depleted of
OCRL1
did not have significantly elevated levels of cellular PIP(2) but displayed an increase in actin comets, as previously observed in cultured cells derived from Lowe patients. Using assays to independently quantitate the endocytic trafficking of megalin and of megalin ligands, we could observe no defect in the trafficking or function of megalin upon
OCRL1
knockdown. Moreover, apical delivery of a newly synthesized marker protein was unaffected.
OCRL1
knockdown did result in a significant increase in secretion of the lysosomal hydrolase
cathepsin D
, consistent with a role for
OCRL1
in membrane trafficking between the trans-Golgi network and endosomes. Together, our studies suggest that
OCRL1
does not directly modulate endocytosis or postendocytic membrane traffic and that the renal manifestations observed in
Lowe syndrome
patients are downstream consequences of the loss of
OCRL1
function.
...
PMID:OCRL1 function in renal epithelial membrane traffic. 1994 34
Mutations in the
OCRL
gene encoding the phosphatidylinositol 4,5-bisphosphate (PI(4,5)P(2)) 5-phosphatase
OCRL
cause
Lowe syndrome (LS)
, which is characterized by intellectual disability, cataracts and selective proximal tubulopathy.
OCRL
localizes membrane-bound compartments and is implicated in intracellular transport. Comprehensive analysis of clathrin-mediated endocytosis in fibroblasts of patients with LS did not reveal any difference in trafficking of epidermal growth factor, low density lipoprotein or transferrin, compared with normal fibroblasts. However, LS fibroblasts displayed reduced mannose 6-phosphate receptor (MPR)-mediated re-uptake of the lysosomal enzyme arylsulfatase B. In addition, endosome-to-trans Golgi network (TGN) transport of MPRs was decreased significantly, leading to higher levels of cell surface MPRs and their enrichment in enlarged, retromer-positive endosomes in
OCRL
-depleted HeLa cells. In line with the higher steady-state concentration of MPRs in the endosomal compartment in equilibrium with the cell surface, anterograde transport of the lysosomal enzyme,
cathepsin D
was impaired. Wild-type
OCRL
counteracted accumulation of MPR in endosomes in an activity-dependent manner, suggesting that PI(4,5)P(2) modulates the activity state of proteins regulated by this phosphoinositide. Indeed, we detected an increased amount of the inactive, phosphorylated form of cofilin and lower levels of the active form of PAK3 upon
OCRL
depletion. Levels of active Rac1 and RhoA were reduced or enhanced, respectively. Overexpression of Rac1 rescued both enhanced levels of phosphorylated cofilin and MPR accumulation in enlarged endosomes. Our data suggest that PI(4,5)P(2) dephosphorylation through
OCRL
regulates a Rac1-cofilin signalling cascade implicated in MPR trafficking from endosomes to the TGN.
...
PMID:The 5-phosphatase OCRL mediates retrograde transport of the mannose 6-phosphate receptor by regulating a Rac1-cofilin signalling module. 2290 55